Literature DB >> 4569060

5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in the treatment of lymphoma.

E Frei, J K Luce, R W Talley, V K Vaitkevicius, H E Wilson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4569060

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN: 0069-0112


× No keyword cloud information.
  6 in total

1.  [Carcinogenic activity of 13 aryldialkyl triazenes in BD-rats (author's transl)].

Authors:  R Preussmann; S Ivankovic; C Landschütz; J Gimmy; E Flohr; U Griesbach
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1974

2.  Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET.

Authors:  David J Straus; Jeffrey L Johnson; Ann S LaCasce; Nancy L Bartlett; Lale Kostakoglu; Eric D Hsi; Heiko Schöder; Nathan C Hall; Sin-Ho Jung; George P Canellos; Lawrence H Schwartz; Ronald W Takvorian; Malik E Juweid; Bruce D Cheson
Journal:  Blood       Date:  2011-02-25       Impact factor: 22.113

Review 3.  N-methyl antitumour agents. A distinct class of anticancer drugs?

Authors:  D Newell; A Gescher; S Harland; D Ross; C Rutty
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

4.  Combination chemotherapy for the treatment of Hodgkin's disease in relapse. Results with lomustine (CCNU), melphalan (Alkeran), and vindesine (DVA) alone (CAD) and in alternation with MOPP and doxorubicin (Adriamycin), bleomycin, and vinblastine (ABV).

Authors:  D J Straus; J Myers; B Koziner; B J Lee; B D Clarkson
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

5.  A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumors.

Authors:  D R Adkins; R Irvin; J Kuhn; D H Boldt; G D Roodman; D Salzman; C Freytes; D D Von Hoff; C F LeMaistre
Journal:  Invest New Drugs       Date:  1993 May-Aug       Impact factor: 3.850

6.  [Results of treatment with ABVD in C-MOPP-resistant Hodgkin's disease (author's transl)].

Authors:  W Gassmann; L Perenyi; H Pralle; M Graubner; N Schmitz; H Löffler
Journal:  Klin Wochenschr       Date:  1981-03-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.